A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L.
Hanel W, et al. Among authors: huang y.
Cancers (Basel). 2023 Feb 24;15(5):1437. doi: 10.3390/cancers15051437.
Cancers (Basel). 2023.
PMID: 36900230
Free PMC article.